TRAIL R-2/DR5, soluble

• Description:

  TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain", which can activate the cell's apoptotic machinery. These receptors are activated by binding to either membrane anchored or soluble TRAIL/Apo2L. Recombinant human soluble TRAIL Receptor-2/DR5 is a 14.9 kDa protein (133 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain.

• Synonyms:

  TNFRSF10B; DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5

• NCBI Gene ID:

  8795

• UniProt:

  O14763

• Accession Number:

  NP_003833.4

• Accession Number mRNA:

  NM_003842.4

• Chromosomal Location:

  8p22-p21

• Reactivity:

  Human

• Cross Reactivity:

  Human

• Sequence:

  MESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES

• Endotoxin:

  < 0.1 ng/µg of protein (< 1EU/µg)

• Purity:

  > 98% by SDS-PAGE & HPLC analyses

• Bioactivity:

  STRAIL Receptor 2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of sTRAIL Receptor 2, TRAIL-induced TNF is suppressed.

• Length:

  133

• Form:

  Lyophilized

• Molecular Weight:

  14.9 kDa

• Host or Source:

  E. coli